網膜芽細胞腫市場：2024年～2031年

レポート概要

世界の網膜芽細胞腫市場は、2023年に9億7,015万米ドルに達し、2031年までには14億4,028万米ドルに達すると予測され、2024年から2031年の予測期間中に5.2%のCAGRで成長すると予測されます。

網膜芽細胞腫は、網膜の組織にできる非常にまれな小児がんです。片目または両眼に発生する可能性があります。網膜芽細胞腫のほとんどの症例は遺伝しませんが、遺伝する症例もあるため、家族歴のある子供は幼少期から目の検査を受ける必要があります。網膜芽細胞腫は一般的に、瞳孔散大検査、検眼、フルオレセイン血管造影検査、網膜電図検査、RB1遺伝子検査、眼球超音波検査、眼球磁気共鳴画像法、場合によっては生検など、さまざまな方法で診断されます。

網膜芽細胞腫の見通しは、治療および早期発見技術の進歩に伴い著しく改善されています。しかし、この疾患は子どもの視力や健康全般に長期的な影響を及ぼす可能性があり、長期的な転帰を管理し、潜在的な問題に対処するために定期的なフォローアップケアが必要です。

市場力学：

促進要因

新薬と治療に対する需要の増加が市場を牽引

新薬や治療に対する需要の増加が市場の成長を後押ししています。近年、小児における網膜芽細胞腫の有病率の増加により、患者の転帰を改善するための革新的な薬剤や治療に対する需要が増加しています。個別化医療は、患者固有の遺伝子プロファイルや疾患の特徴に基づいて個々の患者に合わせた治療を行うもので、網膜芽細胞腫を含む腫瘍学で脚光を浴びるようになりました。網膜芽細胞腫における革新的な薬剤の需要は、より正確で効果的な治療を提供するために継続的に増加しており、より良い治療結果につながる可能性があります。

例えば、2023年2月、Alephoson Biopharmaceuticals Ltd.は、網膜芽細胞腫の治療に有用であると報告されているメルファランに共有結合した細胞透過性ペプチドからなるペプチド-薬物結合体を開示しました。さらに、多くの臨床試験や研究活動が急速に進んでおり、より良い治療のための多くの革新的な発明につながっています。革新的な治療の選択肢には技術的進歩も含まれ、これらの進歩は疾患とそのメカニズムのより良い理解に役立ち、その結果、患者の転帰がより良く改善されます。そのため、多くの臨床試験や研究活動が革新的な治療法のために行われています。

抑制要因

治療に伴う高額な費用などが市場の妨げになると予想されます。標的療法は臨床試験で有望な結果を示していますが、開発・製造にはコストがかかります。これらの革新的な治療法の研究開発費は、臨床試験の実施費用と相まって、これらの薬剤の価格上昇につながる可能性があり、網膜芽細胞腫の治療を求める患者が購入しやすい価格に影響を与えます。

市場セグメンテーション

網膜芽細胞腫市場は、疾患タイプ、用途、エンドユーザー、地域に基づいてセグメント化されます。

遺伝性網膜芽細胞腫セグメントは、網膜芽細胞腫市場シェアの約48.3%を占めています。

遺伝性網膜芽細胞腫は、予測期間中最大の市場シェアを占めると予想されます。非遺伝性網膜芽細胞腫は散発性網膜芽細胞腫としても知られています。網膜芽細胞腫の子どもの約60％が非遺伝性網膜芽細胞腫です。通常、小児はRB1遺伝子の正常なコピーを2つ持って生まれます。網膜芽細胞内のRB1遺伝子の両方のコピーに変異が生じると、網膜芽細胞腫の腫瘍が小児の眼に形成されます。非遺伝性網膜芽細胞腫の子どもは、片眼性網膜芽細胞腫として知られる腫瘍を片方の眼にのみ発症します。通常、RB1変異が将来の子供に遺伝することはありません。

地域別市場分析

北米が網膜芽細胞腫市場シェアの約43.5%を占める

予測期間中、北米地域が最大の市場シェアを占めると予想されます。この地域における技術の進歩は、市場の推進に役立っています。網膜芽細胞腫はまれな疾患ですが、北米ではこの種のがんの有病率が高いです。包括的ながん治療と高度な診断能力が利用可能であるため、疾患のモニタリング、管理、治療が向上します。

米国国立がん研究所によると、米国では年間200人から350人の小児がこの病気と診断されていると推定されています。北米、特に米国には、網膜芽細胞腫の治療薬および治療法の開発と商業化に積極的に関与している大手製薬会社、医療機器メーカー、研究機関がいくつかあります。この地域の確立された製薬・ヘルスケア部門は多額の投資を誘致し、網膜芽細胞腫治療におけるイノベーションを促進しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 新薬と治療に対する需要の増加が市場を牽引
  • 抑制要因
    • 治療に伴う高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ
• PESTEL分析
• 特許分析
• SWOT分析

第6章 疾患タイプ別

• ラテラリティ
• 遺伝性

第7章 治療法別

• 手術療法
• 放射線療法
• 凍結療法
• レーザー療法
• 化学療法
• その他

第8章 エンドユーザー別

• 病院
• 眼科クリニック
• がん研究センター
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市場ポジショニング / シェア分析
• M&A分析

第11章 企業プロファイル

• Pfizer Inc.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主要な発展
• Bristol Myers Squibb Company
• Teva Pharmaceutical Pvt. Ltd.
• Merck and Co.
• Novartis AG
• GlaxoSmithKline Plc
• Johnson & Johnson
• Baxter International Inc.
• AbbVie Inc.
• Hikma Pharmaceuticals Plc（*LIST NOT EXHAUSTIVE）

第12章 付録

Report Overview

The Global Retinoblastoma Market reached US$ 970.15 million in 2023 and is expected to reach US$ 1440.28 million by 2031, growing at a CAGR of 5.2% during the forecast period 2024-2031.

Retinoblastoma is a very rare childhood cancer that forms in the tissues of the retina. It can occur in one or both eyes. Most cases of retinoblastoma are not inherited, but some are, and children with a family history of the disease should have their eyes checked beginning at an early age. Retinoblastoma is generally diagnosed by various methods like examination of dilated pupils, ophthalmoscopy, fluorescein angiography, electroretinography, RB1 gene test, ultrasound examination of the eye, magnetic resonance imaging of the eye, and biopsy in some cases.

The outlook for retinoblastoma has improved significantly as therapy and early detection techniques have advanced. However, the condition can have long-term repercussions on a child's vision and overall health, necessitating regular follow-up care to manage long-term outcomes and handle any potential issues.

Market Dynamics: Drivers

Increasing demand for new drugs and treatments drives the market

The increasing demand for new drugs and treatment drives propels the market growth. In recent years, the demand for innovative drugs and treatments has increased for enhanced patient outcomes due to the increasing prevalence of retinoblastoma in children. Personalized medicine involves tailoring treatments to individual patients based on their unique genetic profile and disease characteristics gained prominence in oncology including retinoblastoma. The demand for innovative drugs in retinoblastoma is continuously increasing to provide more precise and effective therapies, potentially leading to better treatment outcomes.

For instance, in February 2023, Alephoson Biopharmaceuticals Ltd. disclosed peptide-drug conjugates comprising a cell-penetrating peptide covalently linked to melphalan that is reported to be useful for the treatment of retinoblastoma. Moreover, many clinical trials and research activities are going on rapidly, leading to many innovative inventions for better treatment. The innovative treatment options also include technological advancements, these advancements help in a better understanding of the disease and its mechanisms resulting in better and enhanced patient outcomes. Hence, many clinical trials and research activities are being performed for innovative treatment options.

Restraints

Factors such as high costs associated with the treatment is expected to hamper the market. The targeted therapies are showing promising results in clinical trials, but they can be costly to develop and manufacture. The research and development costs for these innovative treatments, coupled with the expenses of conducting clinical trials, may lead to higher prices for these drugs, impacting their affordability for patients seeking retinoblastoma treatment.

Market Segment Analysis

The retinoblastoma market is segmented based on disease type, application, end-user, and region.

The segment inheritance retinoblastoma accounted for approximately 48.3% of the retinoblastoma market share

The inheritance segment is expected to hold the largest market share over the forecast period. The non-hereditary retinoblastoma is also known as sporadic retinoblastoma. About 60% of children with retinoblastoma have non-hereditary retinoblastoma. Commonly, children are born with 2 normal copies of the RB1 gene. A mutation of both copies of the RB1 gene in a retinoblast causes a retinoblastoma tumor to form in the eyes of the children. Children with non-hereditary retinoblastoma only develop a tumor in one eye known as unilateral retinoblastoma. They will not usually pass the RB1 mutation on to their future children.

Market Geographical Analysis

North America accounted for approximately 43.5% of the retinoblastoma market share

North America region is expected to hold the largest market share over the forecast period. The technological advancements in this region, help to propel the market. Though retinoblastoma is a rare disease, there is a high prevalence of this type of cancer in North America. The availability of comprehensive cancer treatments and advanced diagnostic capabilities allows for better disease monitoring, management, and treatment.

According to the National Cancer Institute, there are 200 to 350 children in the United States who are estimated to be diagnosed annually with the disease. North America, especially the United States is home to several major pharmaceutical companies, medical device manufacturers, and research institutions that are actively involved in the development and commercialization of retinoblastoma drugs and treatments. The region's established pharmaceutical and healthcare sectors attract significant investments and foster innovations in retinoblastoma treatments.

Market Segmentation

By Disease Type

Laterality

Unilateral Retinoblastoma

Bilateral Retinoblastoma

Trilateral Retinoblastoma

Inheritance

Hereditary Retinoblastoma

Non-Hereditary Retinoblastoma

By Treatment

Surgery

Radiation Therapy

Cryotherapy

Laser Therapy

Chemotherapy

Cyclophosphamide

Carboplatin

Vincristine

Others

By End-User

Hospitals

Ophthalmic Clinics

Cancer Research Centers

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the retinoblastoma market include Pfizer Inc., Bristol Myers Squibb Company, Teva Pharmaceutical Pvt Ltd., Merck and Co., Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson, Baxter International, Inc., AbbVie Inc., and Hikma Pharmaceuticals Plc among others.

Key Developments

In August 2024, Theriva Biologics Inc. received an FDA-granted rare pediatric drug designation for VCN-01 as a treatment for pediatric patients with retinoblastoma.

In July 2023, the FDA approved a new drug application (NDA) for 200-mg/mL vials of cyclophosphamide injection for use in combination therapy for the treatment of various cancers including retinoblastoma. The approval is expected to demonstrate the safety and efficacy of the product and help the company broaden the available treatment options.

Why Purchase the Report?

To visualize the retinoblastoma market segmentation based on disease type, application, end-user, and region, as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of retinoblastoma market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The retinoblastoma market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disease Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Demand for New Drugs and Treatment Drives the Market
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost Associated with the Treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs
• 5.6. PESTEL Analysis
• 5.7. Patent Analysis
• 5.8. SWOT Analysis

6. By Disease Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 6.1.2. Market Attractiveness Index, By Disease Type
• 6.2. Laterality *
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Inheritance

7. By Treatment

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 7.1.2. Market Attractiveness Index, By Treatment
• 7.2. Surgery*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Radiation Therapy
• 7.4. Cryotherapy
• 7.5. Laser Therapy
• 7.6. Chemotherapy
• 7.7. Others

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.1.2. Market Attractiveness Index, By End-User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Ophthalmic Clinics
• 8.4. Cancer Research Centers
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. UK
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Pfizer Inc. *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Bristol Myers Squibb Company
• 11.3. Teva Pharmaceutical Pvt. Ltd.
• 11.4. Merck and Co.
• 11.5. Novartis AG
• 11.6. GlaxoSmithKline Plc
• 11.7. Johnson & Johnson
• 11.8. Baxter International Inc.
• 11.9. AbbVie Inc.
• 11.10. Hikma Pharmaceuticals Plc (*LIST NOT EXHAUSTIVE)

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us